Merck & Co., Inc. is 237.1x more valuable than Damora Therapeutics, Inc. by market capitalization ($294.13 B vs $1.24 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DMRA | MRK |
|---|---|---|
| Market cap | $1.24 B | $294.13 B |
| US-listed rank | #2475 | #44 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$209.84M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 329 | 996 |
Merck & Co., Inc. is 237.1x more valuable than Damora Therapeutics, Inc. by market capitalization ($294.13 B vs $1.24 B).
Full pages: Damora Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.